Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Silence Therapeutics (SLN) Revenue (2020 - 2025)

Silence Therapeutics' Revenue history spans 6 years, with the latest figure at $34000.0 for Q4 2025.

  • On a quarterly basis, Revenue fell 99.87% to $34000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $535000.0, a 98.76% decrease, with the full-year FY2025 number at $559000.0, down 98.71% from a year prior.
  • Revenue hit $34000.0 in Q4 2025 for Silence Therapeutics, down from $159000.0 in the prior quarter.
  • Over the last five years, Revenue for SLN hit a ceiling of $3775.3 billion in Q2 2021 and a floor of $4335.3 in Q1 2021.
  • Historically, Revenue has averaged $188.8 billion across 5 years, with a median of $4.2 million in 2022.
  • The widest YoY moves for Revenue: up 177002.77% in 2022, down 100.0% in 2022.
  • Tracing SLN's Revenue over 5 years: stood at $4.6 million in 2021, then rose by 21.44% to $5.6 million in 2022, then crashed by 53.39% to $2.6 million in 2023, then surged by 871.33% to $25.3 million in 2024, then plummeted by 99.87% to $34000.0 in 2025.
  • Business Quant data shows Revenue for SLN at $34000.0 in Q4 2025, $159000.0 in Q3 2025, and $200000.0 in Q2 2025.